Mounjaro®
Starting from £179.99/mo
Start journey Learn moreDizziness is a recognised side effect of Wegovy (semaglutide). It appears in the medicine's clinical data and in the official product information, most often during the early weeks of treatment or after a dose increase. For most people it is mild and short-lived, but there are circumstances where it signals something that needs attention. The NHS medicines page for semaglutide lists dizziness among the side effects that can occur, and our prescribers field questions about it most weeks — so if you're experiencing it, you're not alone and you're not imagining things. Wegovy is a prescription-only medicine, and every person using it should be under clinical oversight so that symptoms like these can be put in context for their individual situation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide slows the rate at which the stomach empties and significantly reduces appetite. Both of those effects can reduce total calorie and fluid intake, particularly in the first weeks of treatment. When you're eating and drinking less than usual, blood pressure can drop slightly, especially on standing (a phenomenon called orthostatic hypotension) and that's often the moment dizziness arrives: getting up from a chair, stepping out of bed, or climbing stairs.
Reduced fluid intake compounds this. Nausea is one of Wegovy's most common side effects, and if nausea is putting you off drinking enough water, mild dehydration can follow quickly. That alone is sufficient to produce lightheadedness in otherwise healthy adults.
There is also a direct pharmacological pathway. GLP-1 receptors are present in the central nervous system, and semaglutide's action on those receptors may play a role in the dizziness some people report independently of eating or hydration changes. The full picture is still being studied, which is one reason clinical monitoring during treatment matters. You can read a broader account of Wegovy's side-effect profile on our Wegovy side effects overview page.
Timing follows a fairly consistent pattern. Dizziness tends to peak in the first one to two weeks after starting treatment and again after each dose increase. The Wegovy titration schedule steps up slowly through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, with a minimum of roughly four weeks at each level, that pacing exists partly because it gives the body time to adapt at each stage before moving higher.
For people who move to the higher 7.2 mg dose approved by the MHRA in 2026, the adjustment period can be similarly noticeable. The MHRA's announcement confirming the 7.2 mg single-dose pen approval notes that the starting dose remains 0.25 mg regardless of the intended maintenance level.
Most people find the dizziness eases within a couple of weeks at any given dose. Practical steps that tend to help: rising slowly from sitting or lying, keeping a water bottle close by, and prioritising small amounts of fluid throughout the day even when appetite is low. If dizziness is persistent rather than intermittent, that's worth raising with your prescriber before the next scheduled check-in. Our page on semaglutide and dizziness covers the mechanism in more detail if you'd like to read further.
Most dizziness on Wegovy does not need urgent attention. The version that does looks different: it is sudden, severe, or accompanied by other symptoms rather than occurring in isolation after getting up quickly.
Seek prompt medical help if you experience:
If you're unsure whether your symptoms are within the expected range or not, contacting your prescriber or calling NHS 111 is always the right call. Don't try to manage symptoms you're concerned about alone. The MHRA's Yellow Card scheme is also open to you, reporting your experience contributes to the post-market safety data that helps regulators monitor medicines like Wegovy over time.
Dizziness alone is rarely a reason to avoid semaglutide, but it is absolutely a reason to have a proper conversation before you start. The people most likely to find it disruptive are those already taking medicines that lower blood pressure, or those with a history of fainting. A prescriber reviewing your medical history, current medicines and lifestyle will factor all of that in before recommending a treatment.
If dizziness continues beyond the first month or becomes severe enough to interfere with daily life, your prescriber can review whether something else is going on, whether the titration schedule needs adjusting, or whether semaglutide is the right option for you. The full range of side effects is covered across our Wegovy side-effect pages, including detailed guidance on what people actually experience as a side effect from Wegovy, and our Wegovy overview explains who the medicine is licensed for.
At nume, our prescribers discuss side effects and individual suitability as part of every consultation, not as a box to tick, but because knowing what to expect makes a material difference to how people manage their first weeks on treatment. Some patients are also surprised to find that gas is a side effect of Wegovy, so it is worth reading up on the full picture before you begin. If you'd like to explore whether Wegovy is suitable for you, check your eligibility with a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.